Xencor Initiates Phase 1b/2a Trial of XmAbR5871 for Autoimmune Disease MONROVIA, Calif., February 13, 2013Xencor, Inc. today announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb®5871 in patients with moderate to severe rheumatoid arthritis.
MONROVIA, Calif., January 17, 2013Xencor, Inc. today announced it has received a milestone payment from Janssen Research & Development, LLC (Janssen R&D) resulting from the exercised option for the use of Xencor's Xtend™ half-life extension technology in a therapeutic antibody.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the online publication of first clinical data on the anti-CD19 antibody MOR208 (MOR00208/XmAb5574) in the American Society of Hematology Annual Meeting Abstracts issue of the peer-reviewed medical
Martinsried/Munich, Germany, and Monrovia, Calif., USA, May 22, 2012—MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.
Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement MONROVIA, Calif., April 4, 2012 Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim.
Xencor Initiates Phase 1 Study of XmAb ® 5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response Monrovia, Calif. Oct. 21, 2011 Xencor, Inc., a company using its
Monrovia, Calif. – March 9, 2011 – Xencor, Inc. announced positive results from preclinical studies of XmAb®5871, a humanized monoclonal antibody that dually targets CD19 and CD32b (FcyRIIb) for the treatment of autoimmune diseases, demonstrating that XmAb5871 is a potent suppressor of B cell
Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases Thousand Oaks, Calif. and Monrovia, Calif. (Jan. 6, 2011) Amgen (NASDAQ: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb®5871, an Fc- engineered